The New York State Department of Health (NYS DOH) has issued Rosetta Genomics Ltd a Clinical Laboratory Permit. The permit will enable patients and physicians residing in the state of New York to gain access to the company’s miRview® mets, miRview® squamous, and miRview® meso tests. Rosetta is now working to gain NYS DOH approval for the first of its second generation tests: miRview® mets2.

"We are pleased that these microRNA-based diagnostic products are now available to residents of all 50 US states including New York. Receipt of this permit confirms that Rosetta’s CAP-accredited, CLIA-certified laboratory meets the strict requirements of New York for quality-controlled, accurate, and reliable clinical laboratory services," said Kenneth A. Berlin, president and CEO of Rosetta Genomics. "Rosetta Genomics has made considerable investment in the development of our proprietary microRNA technology platform, and today we have a robust portfolio of diagnostic tests on the market, nearing commercial launch and in development. We look forward to providing the benefits of these powerful diagnostic products to a growing number of clinicians and patients."

Source: Rosetta Genomics